Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy

As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single-chain variable fragment (scFv) antibodies (76clAbs) that block a...

Descripción completa

Detalles Bibliográficos
Autores principales: Minenkova, Olga, Santapaola, Daniela, Milazzo, Ferdinando Maria, Anastasi, Anna Maria, Battistuzzi, Gianfranco, Chiapparino, Caterina, Rosi, Antonio, Gritti, Giuseppe, Borleri, Gianmaria, Rambaldi, Alessandro, Dental, Clélia, Viollet, Cécile, Pagano, Bruno, Salvini, Laura, Marra, Emanuele, Luberto, Laura, Rossi, Antonio, Riccio, Anna, Merlo Pich, Emilio, Santoro, Maria Gabriella, De Santis, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837488/
https://www.ncbi.nlm.nih.gov/pubmed/35167974
http://dx.doi.org/10.1016/j.ymthe.2022.02.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837488/
https://www.ncbi.nlm.nih.gov/pubmed/35167974
http://dx.doi.org/10.1016/j.ymthe.2022.02.013

Ejemplares similares